Universities fill drugmakers' R&D void

10/22/2013 | Forbes

Universities have stepped up their drug discovery efforts as pharmaceutical companies have shuttered research and development labs, former Pfizer global research and development president John LaMattina writes. More universities worldwide are joining the Academic Drug Discovery Consortium, which facilitates the exchange of knowledge and expertise among centers and provides a platform for collaborating with drugmakers, providers and government institutions, including the NIH. Universities benefit through royalties when collaborations result in marketable drugs, as is the case at Princeton University, which has reaped more than $524 million in royalties from cancer drug Alimta.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ